Management of anemia in children receiving chronic dialysis

Meredith A. Atkinson, Bradley A. Warady

Research output: Chapter in Book/Report/Conference proceedingChapter


In 1839, the Scottish physician Robert Christison noted that anemia was a common feature of kidney disease, writing that "no other natural disease came as close to hemorrhage for impoverishing the red particles of the blood" [1, 2]. Anemia is a comorbidity affecting nearly all children treated with chronic dialysis, and its management remains challenging for clinicians. The emergence of recombinant human erythropoietin (rHuEPO) more than 30 years ago revolutionized anemia management in the dialysis population and eliminated dependence on red blood cell transfusions for most patients. Increased understanding of the molecular regulation of EPO production and iron metabolism has opened the door for the development of novel erythropoiesis-stimulating agents (ESA) and renal anemia therapies.

Original languageEnglish (US)
Title of host publicationPediatric Dialysis
Subtitle of host publicationThird Edition
PublisherSpringer International Publishing
Number of pages23
ISBN (Electronic)9783030668617
ISBN (Print)9783030668600
StatePublished - May 1 2021


  • Anemia
  • Dialysis
  • Erythropoietin
  • ESAs
  • Hemoglobin
  • Iron

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Management of anemia in children receiving chronic dialysis'. Together they form a unique fingerprint.

Cite this